First patient treated in Phase II study with IdeS in anti-GBM antibody disease

Hansa Medical AB (publ) today announced that the first patient has been treated with the company lead drug candidate IdeS in an investigator initiated Phase II study in severe anti-GBM antibody disease.Anti-GBM antibody disease, also known as Goodpasture’s disease, is a rare autoimmune disease where autoantibodies directed against type IV collagen cause acute inflammation of the kidney and/or the lungs. In severe anti-GBM, the disease may progress to renal failure or death. The study (ClinicalTrials.gov identifier NCT03157037) is an open label investigator initiated Phase II study in